2021 CMSC Annual Meeting

Tag: (1)Neurology

Poster-Disease-modifying Therapy

Does Frequency and Severity of COVID-19 Differ By Disease Modifying Therapy in MS Patients?

Background: Some authors have reported positive associations between B-cell-depleting (anti-CD20) therapies and COVID-19 infection risk or...

Read More

Poster-Disease-modifying Therapy

Real-Life Experience with Ocrelizumab in Older Patients at an Academic MS Center

Background: Ocrelizumab (OCR) is a B-Cell depleting humanized monoclonal antibody FDA-approved for treatment of relapsing remitting...

Read More

Poster-Disease-modifying Therapy

Characteristics and Outcome of COVID-19 in Patients with Relapsing Multiple Sclerosis Receiving Ofatumumab

Background: A global pandemic of COVID-19 has resulted in over 78 million cases as of 23 December 2020. Risks of COVID-19 in people with...

Read More

Poster-Case Reports / Case Series

Delayed Visual Improvement in Pediatric Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis

Background: Bilateral involvement and severe visual impairment can occur in the acute phase of pediatric myelin oligodendrocyte...

Read More

Platform-Rehabilitation

Beyond the Physical Symptoms of Spasticity for Persons with MS Spasticity: Results from SEEN-MSS, a Large-Scale, Self-Reported Survey

Background: Spasticity, a complex and multi-dimensional symptom of multiple sclerosis (MS), occurs in up to 80% of those with MS. It is...

Read More